Please use this identifier to cite or link to this item:
Title: A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours
Authors: Scott, Edwina N.
Thomas, Anne L.
Molife, L. Rhoda
Ahmed, Samreen
Blagden, Sarah
Fong, Peter C.
Kowal, Kristin
McCoy, Candice
Wiesinger, Herbert
Steward, William P.
De Bono, Johann
First Published: 12-Mar-2009
Publisher: Springer Verlag
Citation: Cancer Chemotherapy and Pharmacology, 2009, 64 (2), pp. 425-429.
Abstract: Purpose: The toxicities, pharmacokinetics and recommended dose of oral once daily ZK 304709, a novel multi-targeted growth inhibitor (MTGI™) with activity against cell-cycle progression and angiogenesis, was investigated in patients by administration for 14 consecutive days followed by 14 days recovery. Methods: Patients with solid tumours resistant to standard treatments were enrolled in an accelerated titration design. Results: Thirty-seven patients received ZK 304709 from 15 to 285 mg daily. The most common drug-related adverse events were vomiting, diarrhoea and fatigue. Systemic exposure to ZK 304709 increased with dose up to 90 mg daily but plateaued thereafter, with high inter-individual variability at all doses. Thirteen patients had stable disease as best response as per RECIST criteria. Conclusions: There was no increase in exposure to ZK 304709 with dose escalation above 90 mg, and the MTD was not determined. This study illustrates the importance of phase I pharmacokinetic data to guide dose escalation and drug development.
DOI Link: 10.1007/s00280-009-0968-y
ISSN: 0344-5704
Type: Article
Description: This is the author's final draft of the paper published as Cancer Chemotherapy and Pharmacology, 2009, 64 (2), pp. 425-429. The original publication is available at Doi: 10.1007/s00280-009-0968-y
Appears in Collections:Published Articles, Dept. of Cancer Studies and Molecular Medicine

Files in This Item:
File Description SizeFormat 
cdk_ccpshort_150209 (final).pdf131.42 kBAdobe PDFView/Open

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.